Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction

Abstract Aims Heart failure is a condition with high mortality rates, and there is a lack of therapies that directly target maladaptive changes in the extracellular matrix (ECM), such as fibrosis. We investigated whether the ECM enzyme known as A disintegrin and metalloprotease with thrombospondin m...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular research 2023-08, Vol.119 (10), p.1915-1927
Main Authors: Vistnes, Maria, Erusappan, Pugazendhi Murugan, Sasi, Athiramol, Nordén, Einar Sjaastad, Bergo, Kaja Knudsen, Romaine, Andreas, Lunde, Ida Gjervold, Zhang, Lili, Olsen, Maria Belland, Øgaard, Jonas, Carlson, Cathrine Rein, Wang, Christian Hjorth, Riise, Jon, Dahl, Christen Peder, Fiane, Arnt Eltvedt, Hauge-Iversen, Ida Marie, Espe, Emil, Melleby, Arne Olav, Tønnessen, Theis, Aronsen, Jan Magnus, Sjaastad, Ivar, Christensen, Geir
Format: Article
Language:eng ; nor
Subjects:
Editor's Choice
Original
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Heart failure is a condition with high mortality rates, and there is a lack of therapies that directly target maladaptive changes in the extracellular matrix (ECM), such as fibrosis. We investigated whether the ECM enzyme known as A disintegrin and metalloprotease with thrombospondin motif (ADAMTS) 4 might serve as a therapeutic target in treatment of heart failure and cardiac fibrosis. Methods and results The effects of pharmacological ADAMTS4 inhibition on cardiac function and fibrosis were examined in rats exposed to cardiac pressure overload. Disease mechanisms affected by the treatment were identified based on changes in the myocardial transcriptome. Following aortic banding, rats receiving an ADAMTS inhibitor, with high inhibitory capacity for ADAMTS4, showed substantially better cardiac function than vehicle-treated rats, including ∼30% reduction in E/e′ and left atrial diameter, indicating an improvement in diastolic function. ADAMTS inhibition also resulted in a marked reduction in myocardial collagen content and a down-regulation of transforming growth factor (TGF)-β target genes. The mechanism for the beneficial effects of ADAMTS inhibition was further studied in cultured human cardiac fibroblasts producing mature ECM. ADAMTS4 caused a 50% increase in the TGF-β levels in the medium. Simultaneously, ADAMTS4 elicited a not previously known cleavage of TGF-β-binding proteins, i.e. latent-binding protein of TGF-β and extra domain A-fibronectin. These effects were abolished by the ADAMTS inhibitor. In failing human hearts, we observed a marked increase in ADAMTS4 expression and cleavage activity. Conclusion Inhibition of ADAMTS4 improves cardiac function and reduces collagen accumulation in rats with cardiac pressure overload, possibly through a not previously known cleavage of molecules that control TGF-β availability. Targeting ADAMTS4 may serve as a novel strategy in heart failure treatment, in particular, in heart failure with fibrosis and diastolic dysfunction. Graphical Abstract Graphical Abstract ADAMTS4 inhibition prevents cardiac fibrosis by reducing the release of ECM-bound TGF-β due to EDA-fibronectin cleavage. TGF, transforming growth factor; ADAMTS4, a disintegrin and metalloprotease with thrombospondin motif; EDA, extra domain A; ECM, extracellular matrix.
ISSN:0008-6363
1755-3245
DOI:10.1093/cvr/cvad078